LMNB2

Summary

LMNB2 (lamin B2, HGNC:6638) is a protein-coding gene on chromosome 19p13.3, encoding Lamin-B2 (Q03252). Lamins are intermediate filament proteins that assemble into a filamentous meshwork, and which constitute the major components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane.

This gene encodes a B type nuclear lamin. The nuclear lamina consists of a two-dimensional matrix of proteins located next to the inner nuclear membrane. The lamin family of proteins make up the matrix and are highly conserved in evolution. During mitosis, the lamina matrix is reversibly disassembled as the lamin proteins are phosphorylated. Lamin proteins are thought to be involved in nuclear stability, chromatin structure and gene expression. Vertebrate lamins consist of two types, A and B. Mutations in this gene are associated with acquired partial lipodystrophy.

Source: NCBI Gene 84823 — RefSeq curated summary.

At a glance

• Gene–disease (curated): progressive myoclonic epilepsy type 9 (Strong, GenCC) — +4 more curated relationships
• Clinical variants (ClinVar): 705 total — 4 pathogenic (top 5% of genes corpus-wide)
• GTEx eGene: eQTL in 8 tissues, sQTL in 3 (q < 0.05)
• Phenotypes (HPO): 66
• Constraint (gnomAD): pLI 1.00 (loss-of-function intolerant), LOEUF 0.40 (moderately constrained)
• MANE Select transcript: NM_032737
• Interaction hub: 2,338 STRING partners (top 5% of genes corpus-wide)

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6638
Approved symbol	LMNB2
Name	lamin B2
Location	19p13.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000176619
Ensembl biotype	protein_coding
OMIM	150341
Entrez	84823

Gene structure

Transcript identifiers

Ensembl transcripts: 20 — 11 protein_coding, 4 protein_coding_CDS_not_defined, 4 nonsense_mediated_decay, 1 retained_intron

MANE Select: ENST00000325327

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 1, TSL 3: 2, TSL 5: 2

ENST00000325327, ENST00000475819, ENST00000490554, ENST00000527409, ENST00000532465, ENST00000534495, ENST00000867388, ENST00000867389, ENST00000917221, ENST00000917222, ENST00000917223, ENST00000917224, ENST00000917225, ENST00000917226, ENST00001007961, ENST00001034820, ENST00001034821, ENST00001073484, ENST00001073485, ENST00001142321

RefSeq mRNA: 1 — MANE Select: NM_032737 NM_032737

CCDS: CCDS12090

Canonical transcript exons

ENST00000325327 — 12 exons

Exon	Start	End
ENSE00000655672	2438163	2438288
ENSE00001052208	2444404	2444540
ENSE00001150160	2438375	2438531
ENSE00001150172	2456670	2456959
ENSE00001247707	2428166	2430952
ENSE00003466453	2431548	2431658
ENSE00003489516	2434295	2434515
ENSE00003497284	2432416	2432523
ENSE00003539631	2434788	2434913
ENSE00003563021	2435001	2435171
ENSE00003588969	2433826	2434105
ENSE00003594665	2431783	2431902

Expression profiles

Bgee: expression breadth ubiquitous, 194 present calls, max score 97.24.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 37.0023 / max 234.9255, expressed in 1815 samples.

Highest expression (Bgee): ventricular zone, testis, ganglionic eminence, endometrium epithelium, embryo.

Genetic regulation across tissues (GTEx eQTL / sQTL)

LMNB2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 8 tissues and its splicing (sQTL) in 3 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

11 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Testis	sqtl	3.0e-07	+0.47	19:2437078:A:G
Muscle Skeletal	eqtl	9.9e-05	-0.18	19:2419362:C:A
Colon Sigmoid	eqtl	2.1e-03	+0.52	19:1892953:C:G
Thyroid	eqtl	1.2e-02	+0.30	19:2975764:G:A
Esophagus Muscularis	eqtl	1.7e-02	+0.32	19:3220865:A:AC
Adipose Subcutaneous	eqtl	1.9e-02	-0.24	19:3143566:C:T
Brain Hypothalamus	sqtl	2.8e-02	+0.47	19:1667051:G:C
Nerve Tibial	eqtl	3.4e-02	+0.32	19:3220865:A:AC
Cells EBV-transformed lymphocytes	sqtl	4.0e-02	-1.53	19:2427943:G:T
Testis	eqtl	4.4e-02	-0.10	19:2419251:T:C
Skin Sun Exposed Lower leg	eqtl	4.5e-02	+0.21	19:1567044:C:T

FANTOM5 promoters

4 alternative TSS:

Promoter ID	TPM avg	Samples expressed
178172	35.3543	1814
178171	1.4369	857
178169	0.1916	72
178170	0.0195	3

Top tissues by expression

showing 100 of 285 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	97.24	gold quality
left testis	UBERON:0004533	95.73	gold quality
right testis	UBERON:0004534	95.62	gold quality
ganglionic eminence	UBERON:0004023	94.82	gold quality
endometrium epithelium	UBERON:0004811	94.78	gold quality
embryo	UBERON:0000922	94.43	gold quality
secondary oocyte	CL:0000655	93.89	gold quality
stromal cell of endometrium	CL:0002255	93.22	gold quality
testis	UBERON:0000473	92.33	gold quality
mucosa of transverse colon	UBERON:0004991	90.95	gold quality
esophagus mucosa	UBERON:0002469	90.17	gold quality
lower esophagus mucosa	UBERON:0035834	90.13	gold quality
hindlimb stylopod muscle	UBERON:0004252	89.53	gold quality
gastrocnemius	UBERON:0001388	89.34	gold quality
apex of heart	UBERON:0002098	88.84	gold quality
muscle of leg	UBERON:0001383	88.70	gold quality
gingival epithelium	UBERON:0001949	88.10	silver quality
oocyte	CL:0000023	87.81	gold quality
cortical plate	UBERON:0005343	87.76	gold quality
right hemisphere of cerebellum	UBERON:0014890	87.41	gold quality
cerebellar hemisphere	UBERON:0002245	86.82	gold quality
esophagus squamous epithelium	UBERON:0006920	86.79	gold quality
cerebellar cortex	UBERON:0002129	86.76	gold quality
epithelium of esophagus	UBERON:0001976	86.34	gold quality
left adrenal gland	UBERON:0001234	86.25	gold quality
right adrenal gland	UBERON:0001233	86.09	gold quality
left adrenal gland cortex	UBERON:0035825	85.98	gold quality
right atrium auricular region	UBERON:0006631	85.78	gold quality
adenohypophysis	UBERON:0002196	85.71	gold quality
esophagus	UBERON:0001043	85.68	gold quality
cerebellum	UBERON:0002037	85.55	gold quality
gingiva	UBERON:0001828	85.52	silver quality
right adrenal gland cortex	UBERON:0035827	85.44	gold quality
heart left ventricle	UBERON:0002084	85.23	gold quality
transverse colon	UBERON:0001157	85.08	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.94	gold quality
vermiform appendix	UBERON:0001154	84.60	gold quality
cardiac ventricle	UBERON:0002082	84.60	gold quality
granulocyte	CL:0000094	84.45	gold quality
adrenal cortex	UBERON:0001235	84.29	gold quality
body of stomach	UBERON:0001161	84.08	gold quality
adrenal gland	UBERON:0002369	84.02	gold quality
cardiac atrium	UBERON:0002081	83.94	gold quality
metanephros cortex	UBERON:0010533	83.87	gold quality
rectum	UBERON:0001052	83.80	gold quality
right lobe of thyroid gland	UBERON:0001119	83.74	gold quality
pituitary gland	UBERON:0000007	83.54	gold quality
squamous epithelium	UBERON:0006914	83.50	gold quality
paraflocculus	UBERON:0005351	83.33	gold quality
sural nerve	UBERON:0015488	83.17	gold quality
monocyte	CL:0000576	83.14	gold quality
heart	UBERON:0000948	83.12	gold quality
ectocervix	UBERON:0012249	83.06	gold quality
mononuclear cell	CL:0000842	83.04	gold quality
right ovary	UBERON:0002118	83.04	gold quality
leukocyte	CL:0000738	82.98	gold quality
left lobe of thyroid gland	UBERON:0001120	82.95	gold quality
stomach	UBERON:0000945	82.82	gold quality
muscle organ	UBERON:0001630	82.76	gold quality
left uterine tube	UBERON:0001303	82.75	gold quality
small intestine Peyer’s patch	UBERON:0003454	82.74	gold quality
left ovary	UBERON:0002119	82.71	gold quality
upper lobe of left lung	UBERON:0008952	82.63	gold quality
adrenal tissue	UBERON:0018303	82.48	gold quality
placenta	UBERON:0001987	82.38	gold quality
right frontal lobe	UBERON:0002810	82.36	gold quality
ileal mucosa	UBERON:0000331	82.32	silver quality
colon	UBERON:0001155	82.12	gold quality
spleen	UBERON:0002106	82.11	gold quality
small intestine	UBERON:0002108	81.94	gold quality
large intestine	UBERON:0000059	81.85	gold quality
body of uterus	UBERON:0009853	81.85	gold quality
intestine	UBERON:0000160	81.84	gold quality
minor salivary gland	UBERON:0001830	81.72	gold quality
cartilage tissue	UBERON:0002418	81.70	silver quality
upper lobe of lung	UBERON:0008948	81.64	gold quality
caecum	UBERON:0001153	81.62	gold quality
prefrontal cortex	UBERON:0000451	81.59	gold quality
skin of abdomen	UBERON:0001416	81.53	gold quality
mouth mucosa	UBERON:0003729	81.53	gold quality
thyroid gland	UBERON:0002046	81.29	gold quality
skin of leg	UBERON:0001511	81.22	gold quality
cingulate cortex	UBERON:0003027	81.18	gold quality
lymph node	UBERON:0000029	81.13	gold quality
lower esophagus	UBERON:0013473	81.07	gold quality
lower esophagus muscularis layer	UBERON:0035833	81.02	gold quality
anterior cingulate cortex	UBERON:0009835	80.98	gold quality
omental fat pad	UBERON:0010414	80.96	gold quality
right lobe of liver	UBERON:0001114	80.95	gold quality
peritoneum	UBERON:0002358	80.92	gold quality
left coronary artery	UBERON:0001626	80.90	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	80.84	gold quality
ovary	UBERON:0000992	80.81	gold quality
vagina	UBERON:0000996	80.68	gold quality
islet of Langerhans	UBERON:0000006	80.67	gold quality
muscle layer of sigmoid colon	UBERON:0035805	80.45	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	80.38	gold quality
Brodmann (1909) area 9	UBERON:0013540	80.31	gold quality
amygdala	UBERON:0001876	80.25	gold quality
smooth muscle tissue	UBERON:0001135	80.12	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.31

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 80 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Thymus	tissue	21.5
Bone marrow	tissue	16.3	medium
Appendix	tissue	14.5	low
Cerebellum	tissue	14.2	high
Placenta	tissue	13.8	low
Locus coeruleus	tissue	13.1
Skeletal muscle	tissue	12.9	medium
Hippocampus	tissue	12.2	high
Lymph node	tissue	12.0	medium
Pituitary gland	tissue	11.9
Vagina	tissue	11.9	low
Small intestine	tissue	11.5	low
Corpus callosum	tissue	11.1
Nucleus accumbens	tissue	11.0
Postcentral gyrus	tissue	10.6
Duodenum	tissue	10.3	low
Colon	tissue	9.9	low
Tonsil	tissue	9.9	medium
Skin 1	tissue	9.6	medium
Choroid plexus	tissue	9.2
Stomach 1	tissue	8.9	medium
Esophagus	tissue	8.9	medium
Midbrain	tissue	8.4
Superior colliculi	tissue	8.3
Medulla oblongata	tissue	8.1
Thalamus	tissue	8.0
Hypothalamus	tissue	7.9
Spinal cord	tissue	7.9
Ovary	tissue	7.8	medium
Substantia nigra	tissue	7.8
Spleen	tissue	7.7	medium
Pons	tissue	7.5
Periaqueductal gray	tissue	7.3
Septum	tissue	7.2
Urinary bladder	tissue	7.0	medium
Ventral forebrain	tissue	7.0
Frontal cortex	tissue	6.9
Cerebral cortex	tissue	6.8	high
Adipose tissue	tissue	6.8	medium
Olfactory bulb	tissue	6.8
Somatosensory cortex	tissue	6.8
Hippocampal formation	tissue	6.7
Putamen	tissue	6.6
Caudate putamen	tissue	6.4
Occipital cortex	tissue	6.4
Motor cortex	tissue	6.3
Amygdala	tissue	6.3
Basal ganglia	tissue	6.1	high
Entorhinal cortex	tissue	6.0
Fallopian tube	tissue	6.0	high
Retrosplenial cortex	tissue	5.9
Prefrontal cortex	tissue	5.8
Rectum	tissue	5.8	medium
Retrosplenial and cingulate cortex	tissue	5.7
Insular cortex	tissue	5.7
Temporal cortex	tissue	5.6
Salivary gland	tissue	5.5	medium
Smooth muscle	tissue	5.2	low
Endometrium 1	tissue	5.0	medium
Lung	tissue	5.0	high

Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Flocculonodular lobe (19.4), Cerebellar cortex (18.5), Vermis (18.5), Ventromedial nucleus (17.6), Arcuate nucleus (16.9).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting LMNB2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 72 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-8067	99.86	69.59	2260
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-4320	99.75	65.80	793
HSA-MIR-1255A	99.74	68.09	744
HSA-MIR-1255B-5P	99.74	68.16	741
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-5004-5P	99.68	66.63	1294
HSA-MIR-29B-2-5P	99.67	68.98	1726
HSA-MIR-6887-3P	99.66	67.83	1778

Functional genomics

gnomAD constraint: pLI 1, LOEUF 0.399, missense Z 0.641 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000325327 splits into 3 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
19:2,430,914–2,438,401	609 / 630.9	0.97	no
19:2,438,402–2,456,873	145 / 228.9	0.63	no
19:2,456,874–2,456,933	35 / 23.9	1.47	no

Literature-anchored findings (GeneRIF, showing 23)

• analysis of protein-DNA interactions at the human lamin B2 replication origin (PMID:12902329)
• The proteins bound in vivo at the LMNB2 replication origin were investigated along the cell cycle. (PMID:12912926)
• This analysis reveals the modular structure of the lamin B2 origin and supports the idea that sequence elements close to the replication start site play an important role in origin activation. (PMID:15024083)
• the distinctive ensemble of heterotypic lamin interactions in a particular cell type affects the stability of the lamin polymer (PMID:15284226)
• the lamin B2 origin adopts a structure partly composed of intramolecular TAT triads (PMID:15611042)
• lamin B was essential for the formation of the mitotic matrix that tethers a number of spindle assembly factors; propose that lamin B is a structural component of the spindle matrix that promotes microtubule assembly and organization in mitosis (PMID:16543417)
• Three new rare heterozygous mutations are the first reported for LMNB2 and are the first reported among patients with acquired partial lipodystrophy. (PMID:16826530)
• human lamin B(2) is indeed synthesized as a longer version than previously reported, because it contains these additional 20 amino acids (PMID:17070523)
• The human DNA replication origin, located in the lamin B2 gene, interacts with the DNA topoisomerases I and II in a cell cycle-modulated manner. (PMID:17290216)
• Using shotgun mass spectrometry, we found this protein differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia. (PMID:19165527)
• These findings indicate that a lamin dimer principally has the freedom for a “combinatorial” head-to-tail association with all types of lamins, a property that might be of significant importance for the assembly of the nuclear lamina. (PMID:20004208)
• Studies indicate that the lamin-binding proteins implicated in laminopathies include lamin B2 and nuclear envelope proteins. (PMID:21400569)
• Mutation in LMNB2 gene is associated with partial lipodystrophy. (PMID:22768673)
• Treating normal human fibroblasts with farnesyltransferase inhibitors causes the accumulation of unprocessed lamin B2 and lamin A and a decrease in mature lamin B1 (PMID:23475125)
• Nuclear envelope remodelling during human spermiogenesis involves somatic B-type lamins and a spermatid-specific B3 lamin isoform. (PMID:25477337)
• Mutation of the nuclear lamin gene LMNB2 in progressive myoclonus epilepsy with early ataxia. (PMID:25954030)
• our studies strongly implicate an overarching role for Lamin B2 in the maintenance of nuclear architecture since loss of Lamin B2 relieves the spatial positional constraints required for maintaining conserved localization of aneuploid chromosome territories in the interphase nucleus. (PMID:26921073)
• Lamin B2 promotes the malignant phenotype of non-small cell lung cancer cells by upregulating dimethylation of histone 3 lysine 9. (PMID:32416090)
• Heterozygous lamin B1 and lamin B2 variants cause primary microcephaly and define a novel laminopathy. (PMID:33033404)
• LMNB2 is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. (PMID:33211382)
• LMNB2 promotes the progression of colorectal cancer by silencing p21 expression. (PMID:33782407)
• Lamin B2 contributes to the proliferation of bladder cancer cells via activating the expression of cell division cycleassociated protein 3. (PMID:35775376)
• The role of lamin B2 in human diseases. (PMID:37044185)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	lmnb2	ENSDARG00000101624
mus_musculus	Lmnb2	ENSMUSG00000062075
rattus_norvegicus	Lmnb2	ENSRNOG00000025742

Paralogs (68): KRT33A (ENSG00000006059), VIM (ENSG00000026025), KRT31 (ENSG00000094796), NEFM (ENSG00000104722), KRT23 (ENSG00000108244), KRT37 (ENSG00000108417), KRT32 (ENSG00000108759), KRT18 (ENSG00000111057), LMNB1 (ENSG00000113368), KRT36 (ENSG00000126337), KRT17 (ENSG00000128422), GFAP (ENSG00000131095), KRT34 (ENSG00000131737), KRT33B (ENSG00000131738), NES (ENSG00000132688), PRPH (ENSG00000135406), KRT85 (ENSG00000135443), KRT7 (ENSG00000135480), KRT71 (ENSG00000139648), INA (ENSG00000148798), LMNTD1 (ENSG00000152936), LMNA (ENSG00000160789), KRT84 (ENSG00000161849), KRT82 (ENSG00000161850), KRT80 (ENSG00000167767), KRT1 (ENSG00000167768), KRT24 (ENSG00000167916), KRT8 (ENSG00000170421), KRT78 (ENSG00000170423), KRT86 (ENSG00000170442), KRT75 (ENSG00000170454), KRT6C (ENSG00000170465), KRT4 (ENSG00000170477), KRT74 (ENSG00000170484), KRT72 (ENSG00000170486), KRT83 (ENSG00000170523), BFSP2 (ENSG00000170819), KRT19 (ENSG00000171345), KRT15 (ENSG00000171346), KRT38 (ENSG00000171360), KRT13 (ENSG00000171401), KRT9 (ENSG00000171403), KRT20 (ENSG00000171431), KRT27 (ENSG00000171446), KRT2 (ENSG00000172867), KRT28 (ENSG00000173908), DES (ENSG00000175084), SYNM (ENSG00000182253), KRT76 (ENSG00000185069), KRT6B (ENSG00000185479), KRT79 (ENSG00000185640), KRT73 (ENSG00000186049), KRT5 (ENSG00000186081), KRT26 (ENSG00000186393), KRT10 (ENSG00000186395), KRT3 (ENSG00000186442), KRT16 (ENSG00000186832), KRT14 (ENSG00000186847), KRT12 (ENSG00000187242), KRT77 (ENSG00000189182)

+8 more (showing top 60).

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:96796) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 16 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal neuronal precursor proliferation	2
abnormal neuronal migration	2
neonatal lethality, complete penetrance	2
decreased brain size	1
abnormal forebrain morphology	1
abnormal cerebral cortex morphology	1
abnormal cerebral cortex lamination	1
abnormal hippocampus layer morphology	1
abnormal cerebellum morphology	1
absent cerebellar foliation	1
thin external granule cell layer	1
respiratory failure	1
increased circulating creatinine level	1
abnormal cortical plate morphology	1
absent Purkinje cell layer	1
disorganized cerebral cortex lamination	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Sus scrofa	Q3ZD69	96.1%	Diamond
Macaca fascicularis	Q4R899	89.8%	Diamond
Caenorhabditis briggsae	Q5WN60	81.1%	Diamond
Gallus gallus	P14731	79.5%	Diamond
Lymnaea stagnalis	Q6QUW1	73.9%	Diamond
Xenopus laevis	P21910	71.1%	Diamond
Hypsibius exemplaris	A0A125S9M6	65.8%	Diamond
Caenorhabditis elegans	Q21443	40.5%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
MIR7108	ncRNA	102466806
TIMM13	protein-coding	26517
TMPRSS9	protein-coding	360200
GADD45B	protein-coding	4616
LINC01775	ncRNA	101928602
SPPL2B	protein-coding	56928
LSM7	protein-coding	51690

Protein

Protein identifiers

Lamin-B2 — Q03252 (reviewed: Q03252)

All UniProt accessions (1): Q03252

UniProt curated annotations — full annotation on UniProt →

Function. Lamins are intermediate filament proteins that assemble into a filamentous meshwork, and which constitute the major components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane. Lamins provide a framework for the nuclear envelope, bridging the nuclear envelope and chromatin, thereby playing an important role in nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics. The structural integrity of the lamina is strictly controlled by the cell cycle, as seen by the disintegration and formation of the nuclear envelope in prophase and telophase, respectively.

Subunit / interactions. Dimer. Lamin dimers then assemble into dimeric head-to-tail polymers. Ultimately, two head-to-tail polymers assemble laterally into a protofilament with a uniformly shaped rod of 3.5 nm in diameter. Interacts with TMEM43.

Subcellular location. Nucleus lamina.

Post-translational modifications. B-type lamins undergo a series of modifications, such as farnesylation and phosphorylation. Increased phosphorylation of the lamins occurs before envelope disintegration and probably plays a role in regulating lamin associations. Phosphorylation plays a key role in lamin organization, subcellular localization and nuclear envelope disintegration. Phosphorylation by CDK1 at Ser-37 and Ser-407 at the onset of mitosis drives lamin disassembly and nuclear envelope breakdown.

Disease relevance. Partial acquired lipodystrophy (APLD) [MIM:608709] A rare childhood disease characterized by loss of subcutaneous fat from the face and trunk. Fat deposition on the pelvic girdle and lower limbs is normal or excessive. Most frequently, onset between 5 and 15 years of age. Most affected subjects are females and some show no other abnormality, but many develop glomerulonephritis, diabetes mellitus, hyperlipidemia, and complement deficiency. Intellectual disability in some cases. APLD is a sporadic disorder of unknown etiology. The disease is caused by variants affecting the gene represented in this entry. Epilepsy, progressive myoclonic 9 (EPM9) [MIM:616540] A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM9 is an autosomal recessive form characterized by myoclonus, tonic-clonic seizures, ataxia, and delayed psychomotor development. The disease may be caused by variants affecting the gene represented in this entry. Microcephaly 27, primary, autosomal dominant (MCPH27) [MIM:619180] A form of microcephaly, a disease defined as a head circumference more than 3 standard deviations below the age, sex and ethnically matched mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small. MCPH27 is an autosomal dominant form apparent in early childhood and associated with global developmental delay, delayed walking, inability to walk, impaired intellectual development, and poor or absent speech. Brain imaging may show enlarged ventricles or gyral abnormalities in some patients. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the intermediate filament family.

RefSeq proteins (1): NP_116126* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001322	Lamin_tail_dom	Domain
IPR018039	IF_conserved	Conserved_site
IPR036415	Lamin_tail_dom_sf	Homologous_superfamily
IPR039008	IF_rod_dom	Domain

Pfam: PF00038, PF00932

UniProt features (60 total): modified residue 13, region of interest 10, strand 10, sequence variant 7, cross-link 5, compositionally biased region 4, domain 2, sequence conflict 2, chain 1, propeptide 1, short sequence motif 1, lipid moiety-binding region 1, glycosylation site 1, helix 1, turn 1

Structure

Experimental structures (PDB)

2 structures by resolution:

PDB	Title	Method	Resolution (Å)
5BNW	The active site of O-GlcNAc transferase imposes constraints on substrate sequence	X-RAY DIFFRACTION	2.4
2LLL	Solution NMR structure of C-terminal globular domain of human Lamin-B2, Northeast …	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q03252-F1	79.82	0.62

Human Protein Atlas

Protein class: Predicted intracellular proteins, Plasma proteins, Disease related genes, Human disease related genes, Congenital disorders of metabolism, Other congenital disorders of metabolism, Congenital malformations, Congenital malformations of the nervous system, Epilepsy

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nuclear membrane

Antibody reliability (HPA): IH enhanced · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (19)

Type	Positions
Phosphothreonine	23, 34
Phosphoserine	37, 316, 407, 420, 422, 424, 426, 497
N6-acetyllysine	81
Omega-n-methylarginine	433
Cysteine methyl ester	617
S-farnesyl cysteine	617
Glycyl lysine isopeptide (lys-gly) (interchain with g-cter in sumo2)	77, 81, 195, 255, 489

Glycosylation sites (1)

Type	Positions
O-linked (glcnac) threonine	413

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 376 (showing top): MORF_DNMT1, MODULE_52, HORIUCHI_WTAP_TARGETS_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, MORF_ESPL1, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GEORGES_CELL_CYCLE_MIR192_TARGETS, MORF_RRM1, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, MODULE_16, PATIL_LIVER_CANCER, PUJANA_CHEK2_PCC_NETWORK, MODULE_118, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC

GO Biological Process (6): nuclear envelope organization (GO:0006998), nuclear migration (GO:0007097), heterochromatin formation (GO:0031507), nuclear pore localization (GO:0051664), protein localization to nuclear envelope (GO:0090435), cytoskeleton organization (GO:0007010)

GO Molecular Function (3): structural constituent of cytoskeleton (GO:0005200), identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (4): nuclear lamina (GO:0005652), intermediate filament (GO:0005882), nuclear membrane (GO:0031965), nuclear envelope (GO:0005635)

GO top-level categories

28 GO namespaces:

Category	Terms
nucleus organization	2
nuclear envelope	2
nucleus	2
endomembrane system organization	1
membrane organization	1
intracellular transport	1
nucleus localization	1
establishment of organelle localization	1
cellular component assembly	1
heterochromatin boundary formation	1
negative regulation of gene expression, epigenetic	1
heterochromatin organization	1
protein-containing complex localization	1
localization within membrane	1
protein localization to nucleus	1
organelle organization	1
structural molecule activity	1
cytoskeleton	1
cytoskeleton organization	1
protein binding	1
binding	1
nuclear periphery	1
cellular anatomical structure	1
intermediate filament cytoskeleton	1
polymeric cytoskeletal fiber	1
organelle membrane	1
endomembrane system	1
organelle envelope	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 2 of 13 annotations. The rest are phylogenetic / computational / electronic (IEA).

2 experimentally-supported GO terms:

GO term	NS	Evidence
nuclear membrane	CC	direct assay
identical protein binding	MF	physical interaction

Protein interactions and networks

STRING

showing 15 of 2,338 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LMNB2	LBR	Q14739	893
LMNB2	TIMM13	P62206	853
LMNB2	SENP2	Q9HC62	759
LMNB2	ACTB	P02570	725
LMNB2	EMD	P50402	717
LMNB2	GAPDH	P00354	684
LMNB2	SENP3	Q9H4L4	655
LMNB2	RGPD1	P0C839	650
LMNB2	TM7SF2	O76062	631
LMNB2	RANGAP1	P46060	622
LMNB2	PXDN	Q92626	610
LMNB2	PXDNL	A1KZ92	610
LMNB2	HMOX1	P09601	607
LMNB2	NFKBIA	P25963	591
LMNB2	LEMD3	Q9Y2U8	587

IntAct

Human interaction partners of LMNB2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

showing 30 of 33 partners by confidence:

Partner	Interaction type	MIscore	Records
LMNB1	physical association	0.850	4
LMNA	physical association	0.850	3
AMOT	physical association	0.560	3
AMOTL2	physical association	0.560	3
CA8	physical association	0.560	3
CCDC120	physical association	0.560	3
CCDC88B	physical association	0.560	3
CDC37	physical association	0.560	3
EFHC2	physical association	0.560	3
FH	physical association	0.560	3
GOLGA2	physical association	0.560	3
LZTS1	physical association	0.560	3
MFAP1	physical association	0.560	3
MID2	physical association	0.560	3
OVOL1	physical association	0.560	3
PIBF1	physical association	0.560	3
POU6F2	physical association	0.560	3
PPP1R13B	physical association	0.560	3
TFIP11	physical association	0.560	3
THAP1	physical association	0.560	3
TP53BP2	physical association	0.560	3
TRIM27	physical association	0.560	3
TSGA10IP	physical association	0.560	3
USP2	physical association	0.560	3
WASHC3	physical association	0.560	3
ZC2HC1C	physical association	0.560	3
ZFHX3	physical association	0.560	3
GPR101	physical association	0.400	1
SFI1	physical association	0.400	1
ZBTB3	physical association	0.400	1

BioGRID (321 interactions; top human partners by supporting records): LMNB1 (Affinity Capture-Western; 15 records), LMNA (Affinity Capture-MS; 14 records), FNTB (Affinity Capture-MS; 3 records), TMPO (Proximity Label-MS; 3 records), ANLN (Affinity Capture-MS; 2 records), ARHGEF1 (Affinity Capture-MS; 2 records), BRD4 (Affinity Capture-MS; 2 records), CDC42 (Affinity Capture-MS; 2 records), CLEC4D (Affinity Capture-MS; 2 records), CLEC4E (Affinity Capture-MS; 2 records), HYPK (Affinity Capture-MS; 2 records), IFITM3 (Affinity Capture-MS; 2 records), MYC (Affinity Capture-MS; 2 records), PARK2 (Affinity Capture-MS; 2 records), PRNP (Affinity Capture-MS; 2 records)

Disease & clinical

Genetic variants

Variant evidence for LMNB2: 705 ClinVar records (4 pathogenic / likely pathogenic). Per-variant detail is on Sugi Variant.

ClinVar

705 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	0
Uncertain significance	318
Likely benign	282
Benign	50

Top pathogenic / likely-pathogenic (4)

Showing all 4 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
997434	NM_032737.4(LMNB2):c.1192G>A (p.Glu398Lys)	Pathogenic	criteria provided, multiple submitters, no conflicts	4
3366973	NM_032737.4(LMNB2):c.578_579del (p.Val193fs)	Pathogenic	criteria provided, single submitter	1
208980	NM_032737.4(LMNB2):c.469C>T (p.His157Tyr)	Pathogenic	no assertion criteria provided	1
997435	NM_032737.4(LMNB2):c.160A>C (p.Asn54His)	Pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore LMNB2’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 35 predictions of 742):

Position(s)	Effect	Δscore	Sites
19:2431546–2431547	donor_loss	1.0000	4
19:2431659–2431660	acceptor_loss	1.0000	5
19:2432414–2432415	donor_loss	1.0000	5
19:2432524–2432525	acceptor_loss	1.0000	3
19:2433817	donor_gain	1.0000
19:2434106–2434107	acceptor_loss	1.0000	4
19:2434293–2434294	donor_loss	1.0000	5
19:2434298	donor_gain	1.0000
19:2434516–2434517	acceptor_loss	1.0000	6
19:2434520	acceptor_gain	1.0000

AlphaMissense

1,018 missense substitutions predicted likely pathogenic (of 4,026 scored), across 345 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
N54	8	0.984	0.998
N490	8	0.957	0.993
D385	8	0.947	0.973
D108	8	0.942	0.977
N210	8	0.929	0.982
F517	8	0.917	0.997
F221	8	0.911	0.981
N71	8	0.903	0.960
D379	8	0.818	0.906
D207	8	0.787	0.881
E387	7	0.990	0.996
W554	7	0.981	0.997
R401	7	0.956	0.990
E398	7	0.948	0.985
E46	7	0.946	0.987
I61	7	0.931	0.997
D55	7	0.926	0.946
E399	7	0.923	0.973
W501	7	0.906	0.990
W548	7	0.892	0.986

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

4 prognostic cancer types:

Cancer	Prognostic	p-value
Lung Adenocarcinoma (TCGA)	unfavorable	5.89e-06
Liver Hepatocellular Carcinoma (TCGA)	unfavorable	0.000174
Prostate Adenocarcinoma (TCGA)	unfavorable	0.000208
Liver Hepatocellular Carcinoma (validation)	unfavorable	0.000394

Disease associations

OMIM: gene MIM:150341 | disease phenotypes: MIM:616540, MIM:619180

GenCC curated gene-disease

5 curated gene-disease records:

Disease	Classification	Inheritance	Records
progressive myoclonic epilepsy type 9	Strong	Autosomal recessive	4
microcephaly 27, primary, autosomal dominant	Strong	Autosomal dominant	4
microcephaly	Moderate	Autosomal dominant
central nervous system malformation	Limited	Autosomal recessive
lipodystrophy, partial, acquired, susceptibility to	Limited	Autosomal dominant	3

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (7 panels, 3 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

7 panels:

Panel	Rating
DDG2P	green
Fetal anomalies	green
Severe microcephaly	green
Hypotonic infant	amber
Intellectual disability	amber
Leukodystrophy, childhood onset	amber
Paediatric disorders	amber

Mondo (5): progressive myoclonic epilepsy type 9 (MONDO:0014685), microcephaly 27, primary, autosomal dominant (MONDO:0030929), central nervous system malformation (MONDO:0020022), lipodystrophy, partial, acquired, susceptibility to (MONDO:0100476), microcephaly (MONDO:0001149)

Orphanet (1): Progressive myoclonic epilepsy type 9 (Orphanet:457265)

HPO phenotypes

showing 60 of 66 phenotypes (HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000028	Cryptorchidism
HP:0000054	Micropenis
HP:0000093	Proteinuria
HP:0000100	Nephrotic syndrome
HP:0000147	Polycystic ovaries
HP:0000171	Microglossia
HP:0000243	Trigonocephaly
HP:0000365	Hearing impairment
HP:0000750	Delayed speech and language development
HP:0000790	Hematuria
HP:0000793	Membranoproliferative glomerulonephritis
HP:0000819	Diabetes mellitus
HP:0000855	Insulin resistance
HP:0001007	Hirsutism
HP:0001182	Tapered finger
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001263	Global developmental delay
HP:0001274	Agenesis of corpus callosum
HP:0001336	Myoclonus
HP:0001382	Joint hypermobility
HP:0001397	Hepatic steatosis
HP:0001840	Metatarsus adductus
HP:0002066	Gait ataxia
HP:0002069	Bilateral tonic-clonic seizure
HP:0002119	Ventriculomegaly
HP:0002123	Generalized myoclonic seizure
HP:0002133	Status epilepticus
HP:0002230	Generalized hirsutism
HP:0002307	Drooling
HP:0002359	Frequent falls
HP:0002650	Scoliosis
HP:0002719	Recurrent infections
HP:0002721	Immunodeficiency
HP:0002829	Arthralgia
HP:0002907	Microscopic hematuria
HP:0002960	Autoimmunity
HP:0003119	Abnormal circulating lipid concentration
HP:0003198	Myopathy
HP:0003577	Congenital onset
HP:0003621	Juvenile onset
HP:0003676	Progressive
HP:0003700	Generalized amyotrophy
HP:0003745	Sporadic
HP:0004209	Clinodactyly of the 5th finger
HP:0005328	Progeroid facial appearance
HP:0005421	Decreased circulating complement C3 concentration
HP:0009002	Loss of truncal subcutaneous adipose tissue
HP:0009019	Progressive loss of facial adipose tissue
HP:0009056	Loss of subcutaneous adipose tissue from upper limbs
HP:0009381	Short finger
HP:0009778	Short thumb
HP:0009879	Simplified gyral pattern
HP:0011451	Primary microcephaly
HP:0011463	Childhood onset
HP:0012450	Chronic constipation
HP:0012510	Extra-axial cerebrospinal fluid accumulation
HP:0030043	Hip subluxation

MeSH disease descriptors

2 disease descriptors:

Descriptor	Name	Tree numbers
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
D009421	Nervous System Malformations	C10.500; C16.131.666

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5465302 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

1 measured of 1 human assays (2 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL5653589	KD	1440 nM

ChEMBL bioactivities

2 potent at pChembl≥5 of 3 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.79	Kd	1629	nM	CHEMBL5653589
5.79	ED50	1629	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 5 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148657: Binding affinity to human LMNB2 incubated for 45 mins by Kinobead based pull down assay	kd	1.6292	uM

CTD chemical–gene interactions

73 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	5
bisphenol A	affects expression, decreases expression, increases expression, affects cotreatment	4
Benzo(a)pyrene	affects methylation, increases expression, increases mutagenesis	3
cobaltous chloride	decreases expression	2
Copper	affects binding, decreases expression	2
Tamoxifen	affects expression, affects cotreatment, decreases expression	2
Valproic Acid	affects expression, increases methylation	2
Cyclosporine	decreases expression, decreases methylation	2
Raloxifene Hydrochloride	affects expression, affects cotreatment, decreases expression	2
afuresertib	decreases expression	1
FR900359	affects phosphorylation	1
bisphenol F	increases expression	1
2,4,6-tribromophenol	decreases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
methylselenic acid	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, increases expression	1
decabromobiphenyl ether	increases expression	1
methylparaben	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
tetrabromobisphenol A	decreases expression	1
zinc chromate	increases abundance, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
coumarin	decreases phosphorylation	1
cupric oxide	decreases expression	1
flavone	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5338472	Binding	Binding affinity to Lmnb2 (unknown origin) assessed as fold change in protein upregulation at 200 uM preincubated for 2 hrs followed by pronase addition and measured after 30 mins by coomassie blue staining based SDS-PAGE gel analysis	Structurally Diverse Alkaloids with Anti-Renal-Fibrosis Activity from the Centipede Scolopendra subspinipes mutilans. — *J Nat Prod*

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SV69	HAP1 LMNB2 (-) 1	Cancer cell line	Male
CVCL_XQ20	HAP1 LMNB2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 211 trials:

NCT	Phase	Status	Title
NCT04586348	Phase 4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	Phase 4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	Phase 3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	Phase 3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	Phase 3	RECRUITING	Reducing Missed Appointments
NCT07377032	Phase 3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	Phase 2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	Phase 2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	Phase 2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	Phase 1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	Phase 1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	Phase 1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT06566066	Not specified	RECRUITING	Register for Patients With Thyroid Hormone Resistance.
NCT01783041	Phase 2/3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	Phase 2/3	COMPLETED	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	Early Phase 1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	COMPLETED	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice
NCT03381027	Not specified	COMPLETED	BABY SMART (Study of Massage Therapy, Sleep And neurodevelopMenT)
NCT03388294	Not specified	COMPLETED	Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders
NCT03410810	Not specified	UNKNOWN	Childhood Outcomes of Preterm Brain Abnormalities
NCT03492060	Not specified	RECRUITING	Longitudinal Study of Neurogenetic Disorders
NCT03577756	Not specified	COMPLETED	Neurodevelopmental Assessment of Infants With Cystic Fibrosis
NCT03654248	Not specified	COMPLETED	Let’s Get Organized in Adult Psychiatric/habilitation Care
NCT03659279	Not specified	COMPLETED	Let’s Get Organized Feasibility Study
NCT03722615	Not specified	COMPLETED	Epidemiology of Congenital Cytomegalovirus in a High HIV Prevalence Setting, South Africa
NCT03770832	Not specified	ACTIVE_NOT_RECRUITING	Wearable Sensors and Video Recordings to Monitor Motor Development
NCT03830879	Not specified	RECRUITING	Shenzhen Birth Cohort Study
NCT03835689	Not specified	COMPLETED	Strongest FamiliesTM Neurodevelopmental
NCT03882788	Not specified	COMPLETED	The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)
NCT03922087	Not specified	COMPLETED	No-worry Baby Project
NCT03977259	Not specified	ACTIVE_NOT_RECRUITING	Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development
NCT04043572	Not specified	UNKNOWN	The Biomarkers of Neurological Disease in Utero Study
NCT04096430	Not specified	RECRUITING	Evaluation of Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach)
NCT04108273	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children
NCT04201509	Not specified	COMPLETED	Validity of Neurocognitive Assessment Methods in Childhood ADHD
NCT04233775	Not specified	UNKNOWN	Altered Cerebral Growth and Development in Infants With Congenital Heart Disease

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for LMNB2 across ~30M SureChEMBL compounds — explore on Sugi Predict.